130 related articles for article (PubMed ID: 38042134)
1. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer.
Hashemi M; Esbati N; Rashidi M; Gholami S; Raesi R; Bidoki SS; Goharrizi MASB; Motlagh YSM; Khorrami R; Tavakolpournegari A; Nabavi N; Zou R; Mohammadnahal L; Entezari M; Taheriazam A; Hushmandi K
Transl Oncol; 2024 Feb; 40():101846. PubMed ID: 38042134
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
3. The Role of Cyanidin-3-
Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
[TBL] [Abstract][Full Text] [Related]
4. FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer.
Hsu HH; Kuo WW; Shih HN; Cheng SF; Yang CK; Chen MC; Tu CC; Viswanadha VP; Liao PH; Huang CY
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623173
[TBL] [Abstract][Full Text] [Related]
5. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
8. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
Zhang Z; Shen C; Zhou F; Zhang Y
Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV Induced miR-134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW-480.
Ye Q; Su L; Chen D; Zheng W; Liu Y
Cell Physiol Biochem; 2017; 43(4):1617-1626. PubMed ID: 29041002
[TBL] [Abstract][Full Text] [Related]
10. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
[TBL] [Abstract][Full Text] [Related]
11. Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells.
Wang Z; Liu J; Yang T; Wang Q; Liang R; Tang J
Mol Cell Biochem; 2023 May; 478(5):1045-1057. PubMed ID: 36219357
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.
Ma Y; Guo C; Wang X; Wei X; Ma J
J Exp Clin Cancer Res; 2023 Sep; 42(1):237. PubMed ID: 37697332
[TBL] [Abstract][Full Text] [Related]
13. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
14. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
[TBL] [Abstract][Full Text] [Related]
15. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.
Lai HH; Lin LJ; Hung LY; Chen PS
Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979
[TBL] [Abstract][Full Text] [Related]
16. Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.
Du W; Yang X; He S; Wang J; Guo Y; Kou B; Jiang Y; Bian P; Li B; Yin L
Drug Deliv; 2021 Dec; 28(1):920-929. PubMed ID: 33974471
[TBL] [Abstract][Full Text] [Related]
17. Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway.
Yin J; Wang L; Wang Y; Shen H; Wang X; Wu L
Onco Targets Ther; 2019; 12():3893-3903. PubMed ID: 31190888
[No Abstract] [Full Text] [Related]
18. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway.
Zhang Y; Ge T; Xiang P; Zhou J; Tang S; Mao H; Tang Q
Onco Targets Ther; 2019; 12():9725-9734. PubMed ID: 32009805
[TBL] [Abstract][Full Text] [Related]
20. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
